Table 5.
Clinical outcomes of NSCLC patients with EGFR kinase domain duplications after EGFRi treatment.
| Mutation | Study (Reference) | EGFR mutation(s), n treated with EGFRi | EGFRi used | Response to EGFRi (PFS) |
|---|---|---|---|---|
| EGFR-KDD | Baik et al. [69] | EGFR-KDD exons 18-25, n = 1 | Gefitinib > Erlotinib | Gefitinib PR (6 years), erlotinib PR (5 years) |
| Gallant et al. [71] | EGFR-KDD exons 18-25, n = 1 | Afatinib | PR (PFS NR) | |
| Wang et al. [68] | EGFR-KDD exons 18-25, n = 1 | Erlotinib > Osimertinib | Erlotinib PD (2 mo), osimertinib PD (2 mo) | |
| EGFR-KDD exons 18-25, n = 1 | Gefitinib > Afatinib > Osimertinib | Gefitinib PR (5 mo), afatinib PD (2 mo), osimertinib PR (4 mo) | ||
| EGFR-KDD exons 18-25, n = 1 | Gefitinib | SD (11 mo) | ||
| EGFR-KDD exons 18-25, n = 1 | Icotinib + Apatinib | PR (4+ mo - PFS not reached) | ||
| EGFR-KDD exons 18-25, n = 1 | Gefitinib > Erlotinib | Gefitinib PD (3 mo), erlotinib PD (5 mo) |
Legend: EGFRi, EGFR inhibitor; EGFR-KDD, EGFR kinase domain duplication; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free survival; NR, not reported;